Feed / SYRE

Spyre Therapeutics, Inc.

SYRE

Healthcare · 108.30 -0.6% today

Partial group confirmationMarket checked 21 Aug, 12:45 GMT-4

Jodie situation report

Spyre Therapeutics, Inc.'s move is being confirmed by its market group.

SYRE accounts for 6.3% of the group's measured movement across 3.7 effective names. raw member direction is mixed; 6 of 10 session-normalized paths align to the upside. Capital-flow agreement is 53%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#5 of 10 by movement share
Group movement share6.3%Absolute path energy—not portfolio weight
Relative path+2.04%aligned
Effective breadth3.7 / 10concentrated
Relative alignment6/10upside path · 0 counter-moving
Capital-flow agreement53%not yet clean
SEQUENCE READ

NTRA, VCYT, CAI moved materially before SYRE. SYRE crossed its material path threshold at 14:35 ET, 65 minutes after the first measured mover. MRNA, GH, COGT followed.

EVIDENCE COVERAGE

5 of 10 members in Cancer Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 7 of 10 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as MYGN begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.

Watch this read

Who this business touches

The relationships behind SYRE

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRKMerck & Company, Inc.partnerFeb 19, 2026 ▾

“We are aware of several companies with product candidates in development for the treatment of patients with IBD, including Merck’s tulisokibart, Roche/Roivant’s afimkibart, and Sanofi/Teva’s duvakitug TL1A antibodies; additional IL-23/IL-23Rs including icotro…”

TAKTakeda Pharmaceutical Company LimitedpartnerFeb 19, 2026 ▾

“hnson & Johnson); α4ß7 antibody Entyvio (Takeda); JAK inhibitors including Xeljanz (Pfizer) and Rinvoq (AbbVie); and S1P1 receptor modulating therapies including Zeposia (Bristol Myers Squibb) and Velsipity (Pfizer).”

Depended on by

ABSIAbsci CorporationcompetitorNov 12, 2025 ▾

“In the broader field of antibody therapeutic development, we may face competition from pharmaceutical and biotechnology companies that are developing therapeutics that address the same disease targets and/or indications addressed by our internally developed p…”

Filing peers

PTGXKYMRORKA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SYRE is currently a Participant in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.